Biotelemetry 10-Q 27 Apr 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 19, 2018
Document and Entity Information
Entity Registrant Name	BIOTELEMETRY, INC.
Entity Central Index Key	1,574,774
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		32,794,129

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 36,346	$ 36,022
Healthcare accounts receivable, net of allowance for doubtful accounts of $18,138 and $15,556, at March 31, 2018 and December 31, 2017, respectively	31,802	25,190
Other accounts receivable, net of allowance for doubtful accounts of $1,536 and $1,425, at March 31, 2018 and December 31, 2017, respectively	15,370	13,296
Inventory	6,353	5,332
Prepaid expenses and other current assets	8,524	10,268
Total current assets	98,395	90,108
Property and equipment, net of accumulated depreciation of $71,996 and $71,902, at March 31, 2018 and December 31, 2017, respectively	47,838	49,194
Intangible assets	137,614	141,707
Goodwill	223,699	223,105
Deferred tax asset	17,988	17,681
Other assets	2,491	2,767
Total assets	528,025	524,562
Current liabilities:
Accounts payable	16,858	14,529
Accrued liabilities	21,639	26,055
Current portion of capital lease obligations	3,817	4,023
Current portion of long-term debt	2,819	2,050
Deferred revenue	5,064	4,298
Total current liabilities	50,197	50,955
Long-term portion of capital lease obligations	726	1,486
Long-term debt	196,336	197,306
Other long-term liabilities	24,412	25,112
Total liabilities	271,671	274,859
Stockholders’ equity:
Common stock—$.001 par value as of March 31, 2018 and December 31, 2017; 200,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 32,794,129 and 32,460,668 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	33	32
Paid-in capital	411,328	409,517
Accumulated other comprehensive loss	(311)	(114)
Accumulated deficit	(152,696)	(158,678)
Total BioTelemetry, Inc.’s stockholders’ equity	258,354	250,757
Noncontrolling interest	(2,000)	(1,054)
Total equity	256,354	249,703
Total liabilities and equity	$ 528,025	$ 524,562

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical - unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance for doubtful accounts - Healthcare accounts receivable (in dollars)	$ 18,138	$ 15,556
Allowance for doubtful accounts - Other accounts receivable (in dollars)	1,536	1,425
Accumulated depreciation	$ 71,996	$ 71,902
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	32,794,129	32,460,668
Common stock, shares outstanding	32,794,129	32,460,668

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Healthcare	$ 80,551	$ 42,511
Research	11,244	9,324
Other	2,701	4,046
Total revenue	94,496	55,881
Cost of revenue:
Healthcare	27,582	14,648
Research	6,326	5,571
Other	2,540	2,753
Total cost of revenue	36,448	22,972
Gross profit	58,048	32,909
Operating expenses:
General and administrative	26,719	15,917
Sales and marketing	11,340	7,701
Bad debt expense	4,879	2,791
Research and development	3,289	2,433
Other charges	5,085	1,739
Total operating expenses	51,312	30,581
Income from operations	6,736	2,328
Other expense:
Interest expense	(1,890)	(388)
Loss on equity method investment	(139)	(95)
Other non-operating income/(expense), net	187	(2,515)
Total other expense	(1,842)	(2,998)
Income/(loss) before income taxes	4,894	(670)
Benefit from income taxes	142	866
Net income	5,036	196
Net loss attributable to noncontrolling interest	(946)	0
Net income attributable to BioTelemetry, Inc.	$ 5,982	$ 196
Net income per common share attributable to BioTelemetry, Inc.:
Basic (in dollars per share)	$ 0.18	$ 0.01
Diluted (in dollars per share)	$ 0.17	$ 0.01
Weighted average number of common shares outstanding:
Basic (in shares)	32,570	28,429
Dilutive stock option and restricted stock units (in shares)	2,665	2,886
Diluted (in shares)	35,235	31,315
Anti-dilutive stock options and restricted stock units excluded from weighted average calculation (in shares)	579	496

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement of Comprehensive Income [Abstract]
Net income attributable to BioTelemetry, Inc.	$ 5,982	$ 196
Foreign currency translation gain/(loss)	(197)	1
Comprehensive income attributable to BioTelemetry, Inc.	$ 5,785	$ 197

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING ACTIVITIES
Net income	$ 5,036	$ 196
Adjustments to reconcile net income to net cash provided by operating activities:
Bad debt expense	4,879	2,791
Depreciation	5,507	2,720
Amortization of intangibles	4,321	995
Stock-based compensation	2,065	3,058
Equity method investment loss	139	95
Change in fair value of acquisition-related contingent consideration	(700)	(605)
Accretion of discount on debt	311	55
Non-cash lease income	(3)	(50)
Non-cash tax benefit	(307)	(635)
Changes in operating assets and liabilities:
Healthcare and other accounts receivables	(13,565)	(7,286)
Inventory	(1,021)	810
Prepaid expenses and other assets	1,287	368
Accounts payable	2,329	463
Accrued and other liabilities	(1,204)	1,678
Net cash provided by operating activities	9,074	4,653
INVESTING ACTIVITIES
Purchases of property and equipment and investment in internally developed software	(3,938)	(2,967)
Net cash used in investing activities	(3,938)	(2,967)
FINANCING ACTIVITIES
Proceeds related to the exercising of stock options and employee stock purchase plan	2,486	2,617
Tax payments related to the vesting of shares	(2,739)	(1,881)
Principal payments on long-term debt	(513)	(312)
Principal payments on capital lease obligations	(966)	(65)
Acquisition of noncontrolling interests	(2,885)	0
Net cash (used in)/provided by financing activities	(4,617)	359
Effect of exchange rate changes on cash	(195)	1
Net increase in cash and cash equivalents	324	2,046
Cash and cash equivalents - beginning of period	36,022	23,052
Cash and cash equivalents - end of period	36,346	25,098
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Non-cash purchases of property and equipment	441	498
Non-cash fair value of equity issued for acquisition of business	1,972	0
Cash paid for interest	1,497	310
Cash paid for taxes	$ 20	$ 47

CONSOLIDATED STATEMENTS OF EQUI

CONSOLIDATED STATEMENTS OF EQUITY (unaudited) - 3 months ended Mar. 31, 2018 - USD ($) $ in Thousands	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interest
Balance at Dec. 31, 2017	$ 249,703	$ 32	$ 409,517	$ (114)	$ (158,678)	$ (1,054)
Balance (in shares) at Dec. 31, 2017	32,460,668	32,460,668
Increase (Decrease) in Shareholders' Equity
Share issuances related to stock compensation plans	$ 2,486	$ 1	2,485
Share issuances related to stock compensation plans (in shares)		354,620
Stock-based compensation	2,065		2,065
Shares withheld to cover taxes on vesting of share based awards	(2,739)		(2,739)
Shares withheld to cover taxes on vesting of share based awards (in shares)		(79,945)
Acquisition of noncontrolling interests	0
Acquisition of noncontrolling interest (in shares)		58,786
Currency translation adjustment	(197)			(197)
Net income/(loss)	5,036				5,982	(946)
Balance at Mar. 31, 2018	$ 256,354	$ 33	$ 411,328	$ (311)	$ (152,696)	$ (2,000)
Balance (in shares) at Mar. 31, 2018	32,794,129	32,794,129

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies a) Principles of Consolidation & Reclassifications The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“ U.S. GAAP ”) for interim financial information, the instructions to Form 10-Q, and Rule 10-01 of Regulation S-X and include the accounts of BioTelemetry, Inc. and its controlled subsidiaries (“ BioTelemetry ,” the “ Company ,” “ we ,” “ our ” or “ us ”). In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of March 31, 2018 and the results of operations and cash flows for the interim periods ended March 31, 2018 and 2017 have been included. All intercompany transactions and balances have been eliminated in consolidation. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 . Certain reclassifications have been made to prior period statements to conform to the current period presentation. These consist of: • reclassifying trade payable invoices received but not yet processed in our purchasing system from accrued liabilities to accounts payable in the consolidated balance sheets, • disaggregating the components of other expense in the consolidated statements of operations, • disaggregating the equity method investment loss from the change in prepaid expenses and other assets in the consolidated statements of cash flows, • reclassifying research and development costs from the Corporate and Other category to the Healthcare segment in our segment information disclosures, and • aggregating the Technology operating segment into the Corporate and Other category. The reclassifications had no impact on previously reported consolidated results of operations, cash flows or accumulated deficit. b) Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. c) Fair Value of Financial Instruments Fair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as defined below. Observable inputs are inputs a market participant would use in valuing an asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our own assumptions about the factors a market participant would use in valuing an asset or liability developed using the best information available in the circumstances. The classification of an asset’s or liability’s level within the fair value hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Level 1 - Quoted prices in active markets for an identical asset or liability. Level 2 - Inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3 - Inputs that are unobservable for the asset or liability, based on our own assumptions about the assumptions a market participant would use in pricing the asset or liability. Our financial instruments consist primarily of cash and cash equivalents, Healthcare accounts receivable, other accounts receivable, accounts payable, short-term debt and long-term debt. With the exception of contingent consideration and long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). Our long-term debt (classified as Level 2) is measured using market prices for similar instruments, inputs such as the borrowing rates currently available, benchmark yields, actual trade data, broker/dealer quotes and other similar data obtained from quoted market prices or independent pricing vendors. The fair value of contingent consideration (classified as Level 3) is measured on a recurring basis using unobservable inputs such as projected payment dates, probabilities of meeting specified milestones and other such variables resulting in payment amounts which are discounted back to present value using a probability-weighted discounted cash flow model. Adjustments to contingent consideration are recorded in other charges in the consolidated statements of operations. In addition to the recurring fair value measurements, the fair value of certain assets acquired and liabilities assumed in connection with a business combination are recorded at fair value, primarily using a discounted cash flow model (classified as Level 3). This valuation technique requires us to make certain assumptions, including, but not limited to, future operating performance and cash flows, royalty rate and other such variables which are discounted to present value using a discount rate that reflects the risk factors associated with future cash flow, the characteristics of the assets acquired and liabilities assumed and the experience of the acquired business. Non-financial assets such as goodwill, intangible assets, and property and equipment are subsequently measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment is recognized. We assess the impairment of intangible assets annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. d) Accounts Receivable and Allowance for Doubtful Accounts Healthcare accounts receivable is related to the Healthcare segment and is recorded at the time revenue is recognized, net of contractual allowances, and is presented on the consolidated balance sheet net of an allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections and the aging of receivables by payor. Because of continuing changes in the health care industry and third-party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows. Other accounts receivable is related to the Research segment and Corporate and Other category and is recorded at the time revenue is recognized, when products are shipped or services are performed. We estimate an allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and the aging of the account. We write-off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. Additionally, we recorded bad debt expense of $4.9 million and $2.8 million for the three months ended March 31, 2018 and March 31, 2017 , respectively. e) Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, Healthcare accounts receivable and other accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written-off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased. At March 31, 2018 and December 31, 2017 , one payor, Medicare, accounted for 16% and 21% , respectively, of our gross accounts receivable. f) Noncontrolling Interest The consolidated financial statements reflect the application of Accounting Standards Codification (“ ASC ”) 810 - Consolidations , which establishes accounting and reporting standards that require: (i) the ownership interest in subsidiaries held by parties other than the parent to be clearly identified and presented in the consolidated balance sheet within stockholders’ equity, but separate from the parent’s equity; (ii) the amount of consolidated net income/(loss) attributable to the parent and the noncontrolling interest to be clearly identified and presented in the consolidated statements of operations; and (iii) changes in a parent’s ownership interest while the parent retains its controlling financial interest in its subsidiary to be accounted for consistently. We acquired approximately 97% of LifeWatch on July 12, 2017. On that date, we acquired control of LifeWatch and began consolidating its financial statements. As of December 31, 2017, we owned 100% of LifeWatch. LifeWatch owns 55% of LifeWatch Turkey Holding AG (“ LifeWatch Turkey ,” domiciled in Switzerland), with their partner, IKSIR TEKNOLOJI SAGLIK VE KIMYA SAN. ve TIC. A.S., a company located in Ankara, Turkey, to provide digital health solutions to the Turkish market. Concurrent with our acquisition of LifeWatch, we acquired control of LifeWatch Turkey and began consolidating their financial statements. As of March 31, 2018 , LifeWatch Turkey’s net assets were $0.1 million and their loss for the three months ended March 31, 2018 was $2.1 million . Amounts pertaining to the noncontrolling ownership interest of LifeWatch Turkey held by third parties are reported as noncontrolling interests in the accompanying consolidated financial statements. g) Stock-Based Compensation ASC 718, Compensation—Stock Compensation (“ ASC 718 ”), addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for: (i) equity instruments of the enterprise or (ii) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the requisite service period (generally, the vesting period of the award). ASC 718 requires that an entity measure the cost of liability-based service awards based on current fair value that is remeasured subsequently at each reporting date through the settlement date. The compensation expense associated with performance stock units (“ PSUs ”) is recognized ratably over the period between when the performance conditions are deemed probable of achievement and when the awards are vested. Performance stock options (“ PSOs ”) are valued and stock-based compensation expense is only recognized once the performance conditions of the outstanding PSOs have been met. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees . We have historically recorded stock-based compensation expense based on the number of options or restricted stock units (“ RSUs ”) we expect to vest using our historical forfeiture experience and periodically update those forfeiture rates to apply to new grants. While we early adopted Accounting Standards Update (“ ASU ”) 2016-09, Improvements to Employee Share-Based Payment Accounting during the year ended December 31, 2016, we have elected to continue to estimate forfeitures under the true-up provision of ASC 718. We record additional expense if the actual forfeiture rate is lower than estimated, and record a recovery of prior expense if the actual forfeiture rate is higher than estimated. We estimate the fair value of our options using the Black‑Scholes option valuation model. The Black‑Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that share‑based awards granted are expected to be outstanding. Other assumptions used in the Black‑Scholes option valuation model include the risk‑free interest rate and expected dividend yield. The risk‑free interest rate for periods pertaining to the expected term of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future. We estimate the fair value of our PSUs using a Monte Carlo simulation. This model uses assumptions, including the risk free interest rate, expected volatility of our stock price and those of the performance group, dividends of the performance group members, and expected life of the awards. As noted above, we continue to estimate forfeitures under the true-up provision of ASC 718. If it becomes probable that the PSU performance targets will be met, compensation expense will be recorded for these awards ratably over the requisite service period. The PSUs are forfeited to the extent the performance criteria are not met. h) Income Taxes We account for income taxes under the liability method, as described in ASC 740 - Income Taxes (“ ASC 740 ”). Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. When we determine that we will not be able to realize our deferred tax assets, we adjust the carrying value of the deferred tax asset through the valuation allowance. We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. On December 22, 2017, the Tax Cuts and Jobs Act (the “ TCJA ”) was enacted in the U.S. The TCJA represents sweeping changes in U.S. tax law. Under ASC 740, the effects of changes in tax rates and laws on deferred tax balances are recognized in the period in which the new legislation is enacted. The total effect of tax law changes on deferred tax balances is recorded as a component of income tax expense. In response to the TCJA, the Staff of the U.S. Securities and Exchange Commission (“ SEC ”) issued Staff Accounting Bulletin No. 118 (“ SAB 118 ”) to provide guidance to registrants in applying ASC 740 in connection with the TCJA. SAB 118 provides that in the period of enactment, the income tax effects of the TCJA may be reported as a provisional amount based on a reasonable estimate (to the extent a reasonable estimate can be determined), which would be subject to adjustment during a measurement period. The measurement period begins in the reporting period of the TCJA’s enactment and ends when a registrant has obtained, prepared, and analyzed the information that was needed in order to complete the accounting requirements under ASC 740. SAB 118 also describes supplemental disclosures that should accompany the provisional amounts. As of December 31, 2017, we applied the guidance in SAB 118 to account for the financial accounting impacts of the TCJA and have provided the applicable supplemental disclosures in “Note 13. Income Taxes.” i) Net Income Per Share We compute net income per share in accordance with ASC 260 - Earnings Per Share . Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by giving effect to all potential dilutive common shares, including stock options and RSUs, using the treasury stock method. Potentially dilutive common shares are not included in the weighted-average shares outstanding for determining net loss per share, as the result would be anti-dilutive. Certain stock options, which are priced higher than the market price of our shares as of March 31, 2018 and 2017 would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income per share. These options could become dilutive in future periods. Similarly, certain recently granted RSUs are also excluded using the treasury stock method as their impact would be anti-dilutive. j) Segment Information ASC 280 - Segment Reporting , establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group in making decisions on how to allocate resources and assess performance. We report our business under two segments: Healthcare and Research. The Healthcare segment is focused on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. We offer cardiologists and electrophysiologists, neurologists and primary care physicians a full spectrum of solutions which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. During the first quarter of 2018, as part of the continuing LifeWatch integration, our forward-looking integration and rebranding plans, considering full year 2018 financial forecasts of the results of the integrated company, and re-evaluating the significance and materiality of our segments, we aggregated the Technology operating segment into the Corporate and Other category. Included in the Corporate and Other category is the manufacturing, testing and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals and corporate overhead and other items not allocated to any of our reportable segments. k) Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In March 2018, the Financial Accounting Standards Board (“ FASB ”) issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 , to add various SEC paragraphs pursuant to the issuance of SAB 118 to ASC 740. SAB 118 was issued by the SEC in December 2017 to provide immediate guidance for accounting implications of U.S. tax reform under the TCJA. We have evaluated the potential impacts of SAB 118 and have applied this guidance to our consolidated financial statements and related disclosures as of January 1, 2018. In May 2017, the FASB released ASU 2017-09, Scope of Modification Accounting , which clarifies the changes to terms or conditions of a share based payment award that requires application of modification accounting under Topic 718. A change to an award should be accounted for as a modification unless the fair value of the modified award is the same as the original award, the vesting conditions do not change and the classification as an equity or liability instrument does not change. This update is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. We adopted this standard effective January 1, 2018, and this standard did not have a material impact on our financial position, results of operations or disclosures. In January 2017, the FASB released ASU 2017-01, Business Combinations: Clarifying the Definition of a Business , which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this ASU should be applied prospectively and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. No disclosures are required at transition. We adopted this standard effective January 1, 2018, and this standard did not have a material impact on our financial position, results of operations or disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , which has been updated through several revisions and clarifications since its original issuance (collectively, the “ Revenue Updates ”). The Revenue Updates require revenue recognized to represent the transfer of promised goods or services to customers at an amount that reflects the consideration that a company expects to receive in exchange for those goods or services. The Revenue Updates also require new, expanded disclosures regarding revenue recognition. We adopted the Revenue Updates effective January 1, 2018. See “Note 2. Revenue Recognition.” Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases . This standard will require lessees to recognize most leases on their balance sheet and makes selected changes to lessor accounting. The standard is effective for annual and interim reporting periods beginning after December 15, 2018. A modified retrospective transition approach is required, with certain practical expedients available. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
Revenue Recognition	Revenue Recognition We adopted ASC 606 - Revenue from Contracts with Customers (“ ASC 606 ” or the “ Revenue Standard ”) on January 1, 2018. The Revenue Standard requires revenue recognized to represent the transfer of promised goods or services to customers at an amount that reflects the consideration that a company expects to receive in exchange for those goods or services. We utilized the modified retrospective method for adoption, allowing us to not retrospectively adjust prior periods. We applied the modified retrospective method only to contracts that were not complete at January 1, 2018 and accounted for the aggregate effect of any contract modifications upon adoption. No cumulative adjustment to retained earnings was recorded. Disaggregation of Revenue We disaggregate revenue from contracts with customers by payor type and major service line. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, amount, timing and uncertainty of our revenue streams. Disaggregated revenue by payor type and major service line for the three months ended March 31, 2018 was as follows: (in thousands) Healthcare Research Other Total Consolidated Payor/Service Line Remote cardiac monitoring services - Medicare $ 30,215 $ — $ — $ 30,215 Remote cardiac monitoring services - commercial payors 50,336 — — 50,336 Clinical trial support and related services — 11,244 — 11,244 Technology devices, consumable and related services — — 2,701 2,701 Total $ 80,551 $ 11,244 $ 2,701 $ 94,496 Remote Cardiac Monitoring Services Revenue (Healthcare segment) Healthcare revenue is generated by remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. We offer cardiologists and electrophysiologists, neurologists and primary care physicians a full spectrum of solutions which provides them with a single source of cardiac monitoring services. We bill our customers after service commences. Performance obligations are determined based on the nature of the services provided by us. With our remote cardiac monitoring services, the patient receives the benefits from the cardiac monitoring service over time, resulting in a time elapsed output method for revenue recognition. We believe that this method provides an accurate depiction of the transfer of value over the term of the performance obligation because the level of effort in providing these services is consistent during the service period. A summary of the payment arrangements with payors is as follows: • Medicare and Contracted payors : We determine the transaction price based negotiated prices for services provided, on a case rate basis, as provided for under the relevant Current Procedural Terminology (“ CPT ”) codes. • Non-contracted payors: Non-contracted commercial and government insurance carriers often reimburse out of network rates provided for under the relevant CPT codes on a case rate basis. Our transaction price includes implicit price concessions based on our historical collection experience for our non-contracted patients We are utilizing the portfolio approach practical expedient in ASC 606 for our patient contracts in the Healthcare segment. We account for the contracts within each portfolio as a collective group, rather than individual contracts. Based on our history with these portfolios and the similar nature and characteristics of the patients within each portfolio, we have concluded that the financial statement effects are not materially different than if accounting for revenue on a contract by contract basis For the contracted portfolio, we have historical experience of collecting substantially all of the negotiated contractual rates and determined at contract inception that these customers have the intention and ability to pay the promised consideration. As such, we are not providing an implicit price concession but, rather, have chosen to accept the risk of default, and adjustments to the transaction price are recorded as bad debt expense. For our non-contracted portfolio, we are providing an implicit price concession because we do not have a contract with the underlying payor, the result of which requires us to estimate our transaction price based on historical cash collections utilizing the expected value method. Subsequent adjustments to the transaction price are recorded as an adjustment to Healthcare revenue and not as bad debt expense. We have not made any significant changes to judgments in applying ASC 606 during the three months ended March 31, 2018 . Clinical Trial Support and Related Services Revenue (Research segment) Research revenue is generated by providing centralized core laboratory services including cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. These amounts are due from pharmaceutical companies and contract research organizations. We bill our customers after the services are performed. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront refundable deposit. Upfront deposits are deferred and then recognized as the services are performed. If a contract is canceled prior to service being provided, the upfront deposit is refunded. Performance obligations are determined based on the nature of the services provided by us. Our core laboratory services are provided over time as the customer receives benefits resulting in revenue recognition over the term of the contract. Our research customer contracts have legally enforceable terms that are predominately thirty days due to termination for convenience clauses, which are held by the customer with no significant penalty. Given the short-term nature of these contracts and the structure of our billing practices, our billing practices approximate our performance if measured by an output method, where each output is an individual occurrence of each performance obligation. Accordingly, we utilize the invoice practical expedient as defined in ASC 606 resulting in recognition of revenue in the amount that we have the right to invoice. We determine the transaction price based on the fixed consideration in our contractual agreements with our customers and allocate the transaction price to each performance obligation based on our relative stand-alone selling prices. We determine the relative stand-alone selling price utilizing either the adjusted market assessment or the cost-plus margin approach depending upon the type of contract. We have not made any significant changes to judgments in applying ASC 606 during the three months ended March 31, 2018 . Technology Devices, Consumable and Related Service Revenue (Other category) Our technology device and other related revenue is primarily derived from two operations: (1) manufacturing, engineering and development of non-invasive cardiac monitors for healthcare companies and (2) manufacturing, engineering and development of cellular-enabled blood glucose meter systems for diabetes patients. We bill our customers after goods are delivered or services are performed. Performance obligations are determined based on the nature of the services provided by us. Our performance obligations consist of the following two categories: (1) the sale of medical devices and related goods produced by us and (2) contract manufacturing on behalf of a customer. These contracts transfer control to a customer at a point in time based on the transfer of title for the underlying good or service. We provide standard warranty provisions. We determine the transaction price based on fixed consideration in our contractual agreements with our customers and allocate the transaction price to each performance obligation based on the relative stand-alone selling price. We determine the relative stand-alone selling price utilizing our observable prices for the sale of the underlying goods. We have not made any significant changes to judgments in applying ASC 606 during the three months ended March 31, 2018 . Deferred Revenue ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g. receivable), before the entity transfers a good or service to the customer. We currently do not have any contract assets. We recognize contract liabilities in the form of deferred revenue in the Research segment in instances where a customer pays an upfront deposit upon contract execution for future services to be performed by us. We receive payments from our customers based on standard terms and conditions. No significant changes or impairment losses occurred to contract balances during the three months ended March 31, 2018 . As of March 31, 2018 , we had deferred revenue of $5.1 million primarily related to the Research services where customers paid upfront deposits upon contract execution for future services to be performed by us. If the contract is canceled, these upfront deposits are refundable if service was not yet provided. For the three months ended March 31, 2018 , amounts moved from deferred revenue to revenue were $1.5 million . Practical Expedient Elections We have elected the following practical expedients in applying ASC 606 across all reportable segments unless otherwise noted below. Unsatisfied Performance Obligations: Because all of our performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in ASC 606 and, therefore, are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Contract Costs: All incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that we otherwise would have recognized is one year or less in duration. Significant Financing Component: We do not adjust the promised amount of consideration for the effects of a significant financing component as we expect, at contract inception, that the period between when we transfer a promised good or service to a customer and when the customer pays for that good or service will be one year or less. Sales Tax Exclusion from the Transaction Price: We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by us from the customer. Shipping and Handling Activities: For our technology device, consumable and related service revenue, we account for shipping and handling activities we perform after a customer obtains control of the good as activities to fulfill the promise to transfer the good.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Acquisitions	Acquisitions LifeWatch On July 12, 2017, we, through our wholly-owned subsidiary Cardiac Monitoring Holding Company, LLC, acquired approximately 97% of the outstanding shares of LifeWatch for aggregate consideration of 3,615,840 shares of BioTelemetry common stock with a fair value of $116.8 million and cash in the amount of $165.8 million . On that date, we acquired control of LifeWatch and began consolidating its financial statements. The acquisition of LifeWatch strengthens our market position as the leader in mobile cardiac monitoring. We recorded our obligations to acquire the remaining untendered LifeWatch shares, pursuant to a squeeze-out procedure in accordance with Swiss law and takeover regulations related to the offering, as components of accrued liabilities and paid-in capital, and reduced our noncontrolling interest related to our ownership of LifeWatch, in our consolidated balance sheet as of December 31, 2017. As a result, we owned 100% of LifeWatch as of December 31, 2017. In early January 2018, we settled those obligations with payment of $2.9 million in cash and the issuance of 58,786 shares of our common stock with a fair market value of $2.0 million . We accounted for the transaction as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the fair value of the purchase price over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities. We recognized $184.1 million of goodwill as a result of the acquisition, all of which has been assigned to the Healthcare segment. None of this goodwill will be deductible for tax purposes. The amounts below represent our preliminary fair value estimates as of March 31, 2018 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period. The measurement period adjustment recorded during the first quarter of 2018 consisted of reducing certain international non-income tax receivables by $0.6 million . The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, including deferred taxes, unrecorded tax provisions and identifiable intangible assets. We expect to finalize all accounting for the acquisition of LifeWatch within one year of the acquisition date. (in thousands, except lives) Amount Weighted Average Life (Years) Fair value of assets acquired: Cash and cash equivalents $ 4,303 Healthcare accounts receivable 9,467 Inventory 1,136 Prepaid expenses and other current assets 3,798 Property and equipment 28,241 Other assets 713 Identifiable intangible assets: Customer relationships 126,900 10 Technology 3,005 3 Total identifiable intangible assets 129,905 Total assets acquired 177,563 Fair value of liabilities assumed: Accounts payable 10,424 Accrued liabilities 9,747 Current portion of capital lease obligations 4,664 Current portion of long-term debt 3,027 Long-term capital lease obligations 3,420 Deferred tax liabilities 14,454 Other long-term liabilities 23,435 Total liabilities assumed 69,171 Total identifiable net assets 108,392 Fair value of noncontrolling interest (9,961 ) Goodwill 184,143 Net assets acquired $ 282,574 We have integrated the operations of LifeWatch which are included as components of our Healthcare segment. As a result of this integration, it is impracticable to disclose the amount of revenue and earnings/(loss) attributable to LifeWatch. There were no acquisition-related costs related to LifeWatch for the three month period ended March 31, 2018 . The following unaudited pro forma financial information has been prepared using historical financial results of BioTelemetry and LifeWatch as if the acquisition had occurred as of January 1, 2016. Certain adjustments related to the elimination of transaction costs, as well as the addition of interest on the debt, the addition of depreciation and amortization related to fair value adjustments on the tangible and identifiable intangible assets acquired, and the change in the share count resulting from the share issuance have been reflected for the purposes of the unaudited pro forma financial information presented below. We believe the assumptions used in preparing the unaudited pro forma financial information are reasonable, but not necessarily indicative of actual results should the acquisition have occurred on January 1, 2016. Pro forma financial information is summarized as follows: Three Months Ended (pro forma, unaudited, in thousands, except per share amounts) March 31, Revenue $ 85,100 Net loss attributable to BioTelemetry, Inc. (6,100 ) Net loss per common share attributable to BioTelemetry, Inc.: Basic $ (0.19 ) Diluted $ (0.19 ) Weighted average number of common shares outstanding: Basic 32,123 Diluted 32,123

Inventory

Inventory	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following: (in thousands) March 31, December 31, Raw materials and supplies $ 3,861 $ 3,128 Finished goods 2,492 2,204 Total inventory $ 6,353 $ 5,332 Inventory, which includes purchased parts, materials, direct labor and applied manufacturing overhead, is stated at the lower of cost or net realizable value, with cost determined by use of the first-in, first-out method.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We have determined that our long term debt, classified as Level 2, has a fair value consistent with its carry value, exclusive of debt discount and deferred charges, of $199.2 million and $199.4 million as of March 31, 2018 and December 31, 2017 , respectively. Contingent consideration represents our contingent milestone payment obligations related to our acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. The balances of the fair value of contingent consideration are recognized within other long-term liabilities on our consolidated balance sheets. Adjustments to contingent consideration are recorded in other charges in the consolidated statements of operations. The following table provides a reconciliation of the beginning and ending balances of contingent payments associated with acquisitions that occurred during the year ended December 31, 2016: Three Months Ended (in thousands) March 31, March 31, Beginning balance $ 700 $ 3,305 Changes in fair value of contingent consideration (700 ) (605 ) Ending balance $ — $ 2,700 During the three months ended March 31, 2018 and 2017 , the fair values of the contingent consideration decreased $0.7 million and $0.6 million , respectively, as it was no longer probable that certain of the contingencies related to the Telcare or ePatch acquisitions, respectively, would be met.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill was recognized at the time of our acquisitions. The following table presents the carrying amount of goodwill allocated to our reportable segments, as well as the changes to goodwill during the three months ended March 31, 2018 : Reporting Segment (in thousands) Healthcare Research Corporate and Other Total Balance at December 31, 2017 $ 198,273 $ 16,293 $ 8,539 $ 223,105 Measurement period adjustment 594 — — 594 Balance at March 31, 2018 $ 198,867 $ 16,293 $ 8,539 $ 223,699 The measurement period adjustment in the Healthcare segment is due to the LifeWatch acquisition. Refer to “Note 3. Acquisitions” for details related to the measurement period adjustment. The gross carrying amounts and accumulated amortization of our intangible assets are as follows: Estimated Useful Life (Years) (in thousands, except years) March 31, December 31, Customer relationships 5 - 15 $ 143,174 $ 143,174 Technology including internally developed software 3 - 10 16,180 15,953 Backlog 1 - 4 6,860 6,860 Covenants not to compete 5 - 7 1,040 1,040 Total intangible assets, gross 167,254 167,027 Customer relationships (14,354 ) (10,868 ) Technology including internally developed software (9,184 ) (8,573 ) Backlog (5,245 ) (5,052 ) Covenants not to compete (857 ) (827 ) Total accumulated amortization (29,640 ) (25,320 ) Total intangible assets, net $ 137,614 $ 141,707

Equity Method Investment

Equity Method Investment	3 Months Ended
	Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	Equity Method Investment We hold an ownership interest in Well Bridge Health, Inc. (“ WellBridge ”). The investment is accounted for under the equity method. Our Chief Executive Officer sits on WellBridge’s Board of Directors, and therefore WellBridge is considered a related party. Except for our periodic investment in WellBridge through capital contributions, there were no related party transactions. As of March 31, 2018 , our investment in WellBridge represented 32.1% of its outstanding stock. A summary of our investment in WellBridge is as follows: Three Months Ended (in thousands) March 31, March 31, Beginning balance $ 1,431 $ 1,125 Loss in equity method investment (139 ) (95 ) Ending balance $ 1,292 $ 1,030

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consists of the following: (in thousands) March 31, December 31, Compensation $ 10,783 $ 13,086 Professional fees 1,904 1,587 Squeeze-out — 2,885 Severance 758 1,605 Non-income taxes 1,345 588 Interest 341 306 Other 6,508 5,998 Total $ 21,639 $ 26,055

Credit Agreement

Credit Agreement	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Credit Agreement	Credit Agreement Concurrent with the acquisition of LifeWatch, we entered into a credit agreement with SunTrust Bank (the “ SunTrust Credit Agreement ”), as a lender and an agent for the lenders (the “ Lenders ”). Pursuant to the SunTrust Credit Agreement, the Lenders agreed to make loans to us as follows; (i) a term loan in an aggregate principal amount equal to $205.0 million ; and (ii) a $50.0 million revolving credit facility for ongoing working capital purposes. The proceeds of the loans were used to pay (i) our existing Healthcare Financial Solutions, LLC Credit Agreement of $24.9 million ; (ii) acquired LifeWatch debt of $3.0 million ; (iii) a portion of the consideration for the acquisition of LifeWatch; and (iv) related transaction fees and expenses for the acquisition of LifeWatch. The loans bear interest at an annual rate, at our election, of (i) with respect to LIBOR rate loans, LIBOR plus the applicable margin and (ii) with respect to base rate loans, the Base Rate (the “ prime rate” as published in the Wall Street Journal plus the applicable margin). The applicable margin for both LIBOR and base rate loans is determined by reference to our Consolidated Total Net Leverage Ratio, as defined in the SunTrust Credit Agreement. As of March 31, 2018 , the applicable margin is 2.00% for LIBOR loans and 1.00% for base rate loans. The outstanding principal of the loan is subject to the following payment schedule: • Beginning January 1, 2018, the principal amount of the term loan will be repaid, on a quarterly basis, in installments of approximately $0.5 million , plus accrued interest; • Beginning January 1, 2019, the principal amount of the term loan will be repaid, on a quarterly basis, in installments of approximately $1.3 million , plus accrued interest; • Beginning January 1, 2020, the principal amount of the term loan will be repaid, on a quarterly basis, in installments of approximately $3.8 million , plus accrued interest; • Beginning January 1, 2021, the principal amount of the term loan will be repaid, on a quarterly basis, in installments of approximately $5.1 million , plus accrued interest; • The remaining principal balance will be repaid on or before July 12, 2022 (or such earlier date upon an acceleration of the loans by Lenders upon an event of default or termination by the Company). The loans are secured by substantially all of our assets and by a pledge of the capital stock of our U.S. based subsidiaries as well as a pledge of 65% of the capital stock of our first tier material foreign subsidiaries, including 65% of our ownership interest of LifeWatch. The carrying amount of the term loan was $199.2 million as of March 31, 2018 , which is the principal amount outstanding, net of $5.3 million of unamortized deferred financing costs to be amortized over the remaining term of the credit facility. The revolving credit facility is subject to an unused commitment fee, which is determined by reference to our Consolidated Total Net Leverage Ratio, as defined in the SunTrust Credit Agreement. Our unused commitment fee as of March 31, 2018 was 0.3% , and the revolving credit facility remains undrawn as of that date. Covenants The SunTrust Credit Agreement contains affirmative and financial covenants regarding the operations of our business and certain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certain investments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, or substantially all, of our property. As of March 31, 2018 , we were in compliance with our covenants.

Equity

Equity	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Equity	Equity Common Stock As of March 31, 2018 and December 31, 2017 , we were authorized to issue 200,000,000 shares of common stock. As of March 31, 2018 and December 31, 2017 , we had 32,794,129 and 32,460,668 shares issued and outstanding, respectively. During the three months ended March 31, 2018, in accordance with the squeeze-out procedures under Swiss law, we issued 58,786 shares to the remaining stockholders of LifeWatch. See “Note 3. Acquisitions” for further details related to the LifeWatch acquisition. Preferred Stock As of March 31, 2018 , we were authorized to issue 10,000,000 shares of preferred stock. As of March 31, 2018 and December 31, 2017 , there were no shares of preferred stock issued or outstanding. Noncontrolling Interest As of March 31, 2018 , the noncontrolling interest of $2.0 million on our consolidated balance sheet represents our partner’s share of the accumulated deficit recorded within LifeWatch Turkey. See “Note 1. Summary of Significant Accounting Policies; f) Noncontrolling Interest” for further details.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation We have three stock plans: our 2017 Omnibus Incentive Plan (“ OIP ”), our 2008 Equity Incentive Plan (the “ 2008 Plan ”) and our 2003 Equity Incentive Plan (the “ 2003 Plan ”). The OIP is the only remaining stock plan actively granting new stock options or units. The purpose of these stock plans was, and the OIP is, to grant incentive stock options to employees and non-qualified stock options, RSUs, performance stock and other stock-based incentive awards to officers, directors, employees and consultants. The Plans are administered by our Board of Directors (the “ Board ”) or its delegates. The number, type, exercise price, and vesting terms of awards are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, but generally not more than ten years from the grant date. Stock option grants to employees generally vest over four years while RSUs generally vest after three years . 2017 Omnibus Incentive Plan (OIP) In May 2017, our stockholders approved the OIP, which replaces the 2008 Plan. Stock options, RSUs, PSUs and PSOs are granted under the OIP. At March 31, 2018 , 2,498,284 shares remain available for grant under the OIP. 2008 Equity Incentive Plan Our 2008 Plan became effective on March 18, 2008 and replaced our 2003 Plan. Under the terms of the 2008 Plan, all available shares in the 2003 Plan share reserve automatically rolled into the 2008 Plan. Any cancellations or forfeitures of granted options under the 2003 Plan also automatically roll into the 2008 Plan. There are no shares available to grant under the 2008 Plan subsequent to the approval of the OIP. Stock option and PSO activity is summarized as follows: Stock Options Performance Stock Options Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Outstanding as of December 31, 2017 3,574,439 $ 10.78 150,000 $ 20.41 Granted 185,806 33.15 — — Forfeited (53,077 ) 28.37 — — Exercised (102,493 ) 12.94 — — Outstanding as of March 31, 2018 3,604,675 $ 11.61 150,000 $ 20.41 The table below summarizes certain additional information with respect to our options: Three Months Ended (in thousands, except per option amounts) March 31, March 31, Aggregate intrinsic value of options outstanding at period end $ 73,400 $ 73,660 Aggregate intrinsic value of options exercisable at period end 65,819 59,376 Aggregate intrinsic value of options exercised during the period 2,164 3,752 Cash received from the exercise of stock options during the period 1,327 1,981 Weighted average grant date fair value per option during the period $ 19.61 $ 15.31 The total compensation cost of options granted but not yet vested at March 31, 2018 was $12.5 million , which is expected to be recognized over a weighted average period of approximately three years. RSU and PSU activity is summarized as follows: Restricted Stock Units Performance Stock Units Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Units outstanding as of December 31, 2017 467,129 $ 13.76 — — Granted 79,474 32.99 63,345 $ 37.79 Forfeited (3,730 ) 17.84 — — Vested (186,650 ) 10.33 — — Units outstanding as of March 31, 2018 356,223 $ 19.81 63,345 $ 37.79 During the three months ended March 31, 2018, we granted awards to certain members of management in the form of PSUs. These PSUs will vest at the end of a three-year performance period only if specific financial performance metrics are met and the vested shares will then be modified based on relative total shareholder return. The 63,345 PSUs were granted at “target” levels, however, for share pool purposes, we have reserved an additional 63,345 shares if the combined financial performance and market conditions achieve maximum levels. As of March 31, 2018 , no compensation expense related to these PSUs was recognized in accordance with ASC 718. Additional information about our RSUs is summarized as follows: Three Months Ended (in thousands) March 31, March 31, Aggregate market value of RSUs vested during the period $ 6,395 $ 4,265 The total compensation cost of RSUs and PSUs granted but not yet vested at March 31, 2018 was $6.8 million , which is expected to be recognized over a weighted average period of approximately two years. Employee Stock Purchase Plan In July 2008, we made available an Employee Stock Purchase Plan (“ 2008 ESPP ”) in which substantially all of our full-time employees became eligible to participate effective March 18, 2008. In May 2017, our stockholders approved the BioTelemetry, Inc. 2017 Employee Stock Purchase Plan (“ 2017 ESPP ”), with 500,000 shares reserved for issuance which replaced the 2008 ESPP. Under the 2017 ESPP, employees may contribute through payroll deductions up to $21,500 . The price per share is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the day of purchase. Proceeds received from the issuance of shares are credited to stockholders’ equity in the period that the shares are issued. For the three months ended March 31, 2018 , an aggregate of 65,477 shares were purchased in accordance with the 2017 ESPP. Net proceeds from the issuance of shares of common stock under the 2017 ESPP for the three months ended March 31, 2018 were $1.2 million . At March 31, 2018 , 387,274 shares remain available for purchase under the 2017 ESPP. Our aggregate stock-based compensation expense is summarized as follows: Three Months Ended (in thousands) March 31, March 31, Stock options $ 1,111 $ 596 Performance stock options — 1,534 Restricted stock units 720 813 Employee stock purchase plan 234 115 Total stock-based compensation expense $ 2,065 $ 3,058

Other Charges

Other Charges	3 Months Ended
	Mar. 31, 2018
Other Income and Expenses [Abstract]
Other Charges	Other Charges We account for expenses associated with exit or disposal activities in accordance with ASC 420 - Exit or Disposal Cost Obligations, and record the expenses in other charges in our consolidated statements of operations, and record the related accrual in the accrued expenses line of our consolidated balance sheets. We account for expenses associated with our acquisitions and certain litigation as other charges as incurred. These expenses were primarily a result of activities surrounding our acquisition and legal fees related to patent litigation in which we are the plaintiff. Other charges are costs that are not considered necessary to the ongoing business operations. A summary of these expenses is as follows: Three Months Ended (in thousands) March 31, March 31, Legal fees $ 1,536 $ 982 Professional fees 1,227 1,160 Severance and employee related costs 1,997 185 Change in fair value of contingent consideration (700 ) (605 ) Other costs 1,025 17 Total $ 5,085 $ 1,739 Legal fees, severance and employee related costs and other costs increased primarily due to integration activities related to the LifeWatch acquisition. The change in fair value of contingent consideration is the result of the contingent consideration related to certain 2016 acquisitions being written off as it is no longer probable that certain of the contingencies will be met.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The income tax provision for interim periods is determined using an estimated annual effective tax rate adjusted for discrete items, if any, which are taken into account in the quarterly period in which they occur. We review and update our estimated annual effective tax rate each quarter. An income tax benefit of $0.1 million and $0.9 million was recorded for the three months ended March 31, 2018 and 2017 , respectively, primarily due to a discrete benefit recorded for equity compensation deduction under the previously adopted ASU 2016-9, Improvement to Employee Share Based Payment Accounting . At March 31, 2018 and December 31, 2017 , we had deferred tax assets, net of deferred tax liabilities and valuation allowance, of $18.0 million and $17.7 million , respectively. On December 22, 2017, the TCJA was enacted in the U.S. The TCJA represents sweeping changes in U.S. tax law. As of December 31, 2017, we recorded the provisional impact from the TCJA in accordance with SAB 118. As of March 31, 2018, we have not adjusted any of our provisional amounts that were recorded as of December 31, 2017. We will finalize our adjustments during 2018.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Information	Segment Information We operate under two reportable segments: Healthcare and Research. During the first quarter of 2018, we aggregated the Technology operating segment into the “Corporate and Other” category. The Healthcare segment is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. We offer cardiologists and electrophysiologists, neurologists and primary care physicians a full spectrum of solutions which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. Included in the Corporate and Other category is the manufacturing, testing and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals and corporate overhead and other items not allocated to any of our reportable segments. Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses including integration, restructuring and other charges, as well as the elimination of costs associated with intercompany revenue are included in Corporate and Other. Also included in Corporate and Other is our net interest expense and other financing expenses. We do not allocate assets to the individual segments. During the year ended December 31, 2017 we reclassified research and development costs associated with cardiovascular devices utilized by our Research segment from the Corporate and Other category to the Healthcare segment to synchronize our external reporting with the way our chief operating decision maker reviews the segment performance and makes decisions about the reportable segments. (in thousands) Healthcare Research Corporate and Other Consolidated Three Months Ended March 31, 2018 Revenue $ 80,551 $ 11,244 $ 2,701 $ 94,496 Income/(loss) before income taxes 17,724 786 (13,616 ) 4,894 Depreciation and amortization 11,436 1,010 (2,618 ) 9,828 Capital expenditures 5,064 291 (1,417 ) 3,938 (reclassified, in thousands) Healthcare Research Corporate and Other Consolidated Three Months Ended March 31, 2017 Revenue $ 42,511 $ 9,324 $ 4,046 $ 55,881 Income/(loss) before income taxes 11,759 378 (12,807 ) (670 ) Depreciation and amortization 2,861 1,033 (179 ) 3,715 Capital expenditures 2,890 — 77 2,967

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2018
Legal Proceedings
Legal Proceedings	Legal Proceedings The final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be estimated. ZTech, Inc., Biorita LLC, and the Cleveland Clinic Foundation Arbitration In January 2017, ZTech, Inc., Biorita LLC, and the Cleveland Clinic Foundation (the “ Claimants ”) filed an arbitration demand against LifeWatch with the American Arbitration Association. Claimants alleged that LifeWatch violated the 2015 Stock Purchase Agreement for the purchase of FlexLife Health, Inc., a remote international normalized ratio monitoring business. The demand alleges LifeWatch did not make commercially reasonable efforts to achieve certain conditions precedent and did not have a reasonable basis for terminating the business line. Claimants seek liquidated damages and attorneys’ fees. We are vigorously defending against these claims and are seeking recovery of attorneys’ fees related to our defense. The arbitration hearing was held in February 2018, and we are awaiting a decision. While we believe that the risk of loss in this arbitration is improbable, we cannot determine, nor can we estimate, the range of potential loss. Accordingly, as we do not believe that a loss is probable, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this matter.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation & Reclassifications	Principles of Consolidation & Reclassifications The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“ U.S. GAAP ”) for interim financial information, the instructions to Form 10-Q, and Rule 10-01 of Regulation S-X and include the accounts of BioTelemetry, Inc. and its controlled subsidiaries (“ BioTelemetry ,” the “ Company ,” “ we ,” “ our ” or “ us ”). In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of March 31, 2018 and the results of operations and cash flows for the interim periods ended March 31, 2018 and 2017 have been included. All intercompany transactions and balances have been eliminated in consolidation. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 . Certain reclassifications have been made to prior period statements to conform to the current period presentation. These consist of: • reclassifying trade payable invoices received but not yet processed in our purchasing system from accrued liabilities to accounts payable in the consolidated balance sheets, • disaggregating the components of other expense in the consolidated statements of operations, • disaggregating the equity method investment loss from the change in prepaid expenses and other assets in the consolidated statements of cash flows, • reclassifying research and development costs from the Corporate and Other category to the Healthcare segment in our segment information disclosures, and • aggregating the Technology operating segment into the Corporate and Other category. The reclassifications had no impact on previously reported consolidated results of operations, cash flows or accumulated deficit.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as defined below. Observable inputs are inputs a market participant would use in valuing an asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our own assumptions about the factors a market participant would use in valuing an asset or liability developed using the best information available in the circumstances. The classification of an asset’s or liability’s level within the fair value hierarchy is determined based on the lowest level input that is significant to the fair value measurement. Level 1 - Quoted prices in active markets for an identical asset or liability. Level 2 - Inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3 - Inputs that are unobservable for the asset or liability, based on our own assumptions about the assumptions a market participant would use in pricing the asset or liability. Our financial instruments consist primarily of cash and cash equivalents, Healthcare accounts receivable, other accounts receivable, accounts payable, short-term debt and long-term debt. With the exception of contingent consideration and long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). Our long-term debt (classified as Level 2) is measured using market prices for similar instruments, inputs such as the borrowing rates currently available, benchmark yields, actual trade data, broker/dealer quotes and other similar data obtained from quoted market prices or independent pricing vendors. The fair value of contingent consideration (classified as Level 3) is measured on a recurring basis using unobservable inputs such as projected payment dates, probabilities of meeting specified milestones and other such variables resulting in payment amounts which are discounted back to present value using a probability-weighted discounted cash flow model. Adjustments to contingent consideration are recorded in other charges in the consolidated statements of operations. In addition to the recurring fair value measurements, the fair value of certain assets acquired and liabilities assumed in connection with a business combination are recorded at fair value, primarily using a discounted cash flow model (classified as Level 3). This valuation technique requires us to make certain assumptions, including, but not limited to, future operating performance and cash flows, royalty rate and other such variables which are discounted to present value using a discount rate that reflects the risk factors associated with future cash flow, the characteristics of the assets acquired and liabilities assumed and the experience of the acquired business. Non-financial assets such as goodwill, intangible assets, and property and equipment are subsequently measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment is recognized. We assess the impairment of intangible assets annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Healthcare accounts receivable is related to the Healthcare segment and is recorded at the time revenue is recognized, net of contractual allowances, and is presented on the consolidated balance sheet net of an allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections and the aging of receivables by payor. Because of continuing changes in the health care industry and third-party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows. Other accounts receivable is related to the Research segment and Corporate and Other category and is recorded at the time revenue is recognized, when products are shipped or services are performed. We estimate an allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and the aging of the account. We write-off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, Healthcare accounts receivable and other accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written-off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.
Noncontrolling Interests	Noncontrolling Interest The consolidated financial statements reflect the application of Accounting Standards Codification (“ ASC ”) 810 - Consolidations , which establishes accounting and reporting standards that require: (i) the ownership interest in subsidiaries held by parties other than the parent to be clearly identified and presented in the consolidated balance sheet within stockholders’ equity, but separate from the parent’s equity; (ii) the amount of consolidated net income/(loss) attributable to the parent and the noncontrolling interest to be clearly identified and presented in the consolidated statements of operations; and (iii) changes in a parent’s ownership interest while the parent retains its controlling financial interest in its subsidiary to be accounted for consistently.
Stock-based Compensation	Stock-Based Compensation ASC 718, Compensation—Stock Compensation (“ ASC 718 ”), addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for: (i) equity instruments of the enterprise or (ii) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the requisite service period (generally, the vesting period of the award). ASC 718 requires that an entity measure the cost of liability-based service awards based on current fair value that is remeasured subsequently at each reporting date through the settlement date. The compensation expense associated with performance stock units (“ PSUs ”) is recognized ratably over the period between when the performance conditions are deemed probable of achievement and when the awards are vested. Performance stock options (“ PSOs ”) are valued and stock-based compensation expense is only recognized once the performance conditions of the outstanding PSOs have been met. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees . We have historically recorded stock-based compensation expense based on the number of options or restricted stock units (“ RSUs ”) we expect to vest using our historical forfeiture experience and periodically update those forfeiture rates to apply to new grants. While we early adopted Accounting Standards Update (“ ASU ”) 2016-09, Improvements to Employee Share-Based Payment Accounting during the year ended December 31, 2016, we have elected to continue to estimate forfeitures under the true-up provision of ASC 718. We record additional expense if the actual forfeiture rate is lower than estimated, and record a recovery of prior expense if the actual forfeiture rate is higher than estimated. We estimate the fair value of our options using the Black‑Scholes option valuation model. The Black‑Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that share‑based awards granted are expected to be outstanding. Other assumptions used in the Black‑Scholes option valuation model include the risk‑free interest rate and expected dividend yield. The risk‑free interest rate for periods pertaining to the expected term of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future. We estimate the fair value of our PSUs using a Monte Carlo simulation. This model uses assumptions, including the risk free interest rate, expected volatility of our stock price and those of the performance group, dividends of the performance group members, and expected life of the awards. As noted above, we continue to estimate forfeitures under the true-up provision of ASC 718. If it becomes probable that the PSU performance targets will be met, compensation expense will be recorded for these awards ratably over the requisite service period. The PSUs are forfeited to the extent the performance criteria are not met.
Income Taxes	Income Taxes We account for income taxes under the liability method, as described in ASC 740 - Income Taxes (“ ASC 740 ”). Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. When we determine that we will not be able to realize our deferred tax assets, we adjust the carrying value of the deferred tax asset through the valuation allowance. We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. On December 22, 2017, the Tax Cuts and Jobs Act (the “ TCJA ”) was enacted in the U.S. The TCJA represents sweeping changes in U.S. tax law. Under ASC 740, the effects of changes in tax rates and laws on deferred tax balances are recognized in the period in which the new legislation is enacted. The total effect of tax law changes on deferred tax balances is recorded as a component of income tax expense. In response to the TCJA, the Staff of the U.S. Securities and Exchange Commission (“ SEC ”) issued Staff Accounting Bulletin No. 118 (“ SAB 118 ”) to provide guidance to registrants in applying ASC 740 in connection with the TCJA. SAB 118 provides that in the period of enactment, the income tax effects of the TCJA may be reported as a provisional amount based on a reasonable estimate (to the extent a reasonable estimate can be determined), which would be subject to adjustment during a measurement period. The measurement period begins in the reporting period of the TCJA’s enactment and ends when a registrant has obtained, prepared, and analyzed the information that was needed in order to complete the accounting requirements under ASC 740. SAB 118 also describes supplemental disclosures that should accompany the provisional amounts. As of December 31, 2017, we applied the guidance in SAB 118 to account for the financial accounting impacts of the TCJA and have provided the applicable supplemental disclosures in “Note 13. Income Taxes.”
Net Income Per Share	Net Income Per Share We compute net income per share in accordance with ASC 260 - Earnings Per Share . Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by giving effect to all potential dilutive common shares, including stock options and RSUs, using the treasury stock method. Potentially dilutive common shares are not included in the weighted-average shares outstanding for determining net loss per share, as the result would be anti-dilutive. Certain stock options, which are priced higher than the market price of our shares as of March 31, 2018 and 2017 would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income per share. These options could become dilutive in future periods. Similarly, certain recently granted RSUs are also excluded using the treasury stock method as their impact would be anti-dilutive.
Segment Information	Segment Information ASC 280 - Segment Reporting , establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group in making decisions on how to allocate resources and assess performance. We report our business under two segments: Healthcare and Research. The Healthcare segment is focused on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. We offer cardiologists and electrophysiologists, neurologists and primary care physicians a full spectrum of solutions which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. During the first quarter of 2018, as part of the continuing LifeWatch integration, our forward-looking integration and rebranding plans, considering full year 2018 financial forecasts of the results of the integrated company, and re-evaluating the significance and materiality of our segments, we aggregated the Technology operating segment into the Corporate and Other category. Included in the Corporate and Other category is the manufacturing, testing and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals and corporate overhead and other items not allocated to any of our reportable segments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In March 2018, the Financial Accounting Standards Board (“ FASB ”) issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 , to add various SEC paragraphs pursuant to the issuance of SAB 118 to ASC 740. SAB 118 was issued by the SEC in December 2017 to provide immediate guidance for accounting implications of U.S. tax reform under the TCJA. We have evaluated the potential impacts of SAB 118 and have applied this guidance to our consolidated financial statements and related disclosures as of January 1, 2018. In May 2017, the FASB released ASU 2017-09, Scope of Modification Accounting , which clarifies the changes to terms or conditions of a share based payment award that requires application of modification accounting under Topic 718. A change to an award should be accounted for as a modification unless the fair value of the modified award is the same as the original award, the vesting conditions do not change and the classification as an equity or liability instrument does not change. This update is effective for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2017. We adopted this standard effective January 1, 2018, and this standard did not have a material impact on our financial position, results of operations or disclosures. In January 2017, the FASB released ASU 2017-01, Business Combinations: Clarifying the Definition of a Business , which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The amendments in this ASU should be applied prospectively and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. No disclosures are required at transition. We adopted this standard effective January 1, 2018, and this standard did not have a material impact on our financial position, results of operations or disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers , which has been updated through several revisions and clarifications since its original issuance (collectively, the “ Revenue Updates ”). The Revenue Updates require revenue recognized to represent the transfer of promised goods or services to customers at an amount that reflects the consideration that a company expects to receive in exchange for those goods or services. The Revenue Updates also require new, expanded disclosures regarding revenue recognition. We adopted the Revenue Updates effective January 1, 2018. See “Note 2. Revenue Recognition.” Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02, Leases . This standard will require lessees to recognize most leases on their balance sheet and makes selected changes to lessor accounting. The standard is effective for annual and interim reporting periods beginning after December 15, 2018. A modified retrospective transition approach is required, with certain practical expedients available. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2018
Deferred Revenue Disclosure [Abstract]
Disaggregation of Revenue	Disaggregated revenue by payor type and major service line for the three months ended March 31, 2018 was as follows: (in thousands) Healthcare Research Other Total Consolidated Payor/Service Line Remote cardiac monitoring services - Medicare $ 30,215 $ — $ — $ 30,215 Remote cardiac monitoring services - commercial payors 50,336 — — 50,336 Clinical trial support and related services — 11,244 — 11,244 Technology devices, consumable and related services — — 2,701 2,701 Total $ 80,551 $ 11,244 $ 2,701 $ 94,496

Acquisitions (Tables)

Acquisitions (Tables) - LifeWatch	3 Months Ended
	Mar. 31, 2018
Acquisitions
Schedule of total consideration and related allocation for net assets acquired	The amounts below represent our preliminary fair value estimates as of March 31, 2018 and are subject to subsequent adjustment as additional information is obtained during the applicable measurement period. The measurement period adjustment recorded during the first quarter of 2018 consisted of reducing certain international non-income tax receivables by $0.6 million . The primary areas of these preliminary estimates that are not yet finalized relate to certain tangible assets acquired and liabilities assumed, including deferred taxes, unrecorded tax provisions and identifiable intangible assets. We expect to finalize all accounting for the acquisition of LifeWatch within one year of the acquisition date. (in thousands, except lives) Amount Weighted Average Life (Years) Fair value of assets acquired: Cash and cash equivalents $ 4,303 Healthcare accounts receivable 9,467 Inventory 1,136 Prepaid expenses and other current assets 3,798 Property and equipment 28,241 Other assets 713 Identifiable intangible assets: Customer relationships 126,900 10 Technology 3,005 3 Total identifiable intangible assets 129,905 Total assets acquired 177,563 Fair value of liabilities assumed: Accounts payable 10,424 Accrued liabilities 9,747 Current portion of capital lease obligations 4,664 Current portion of long-term debt 3,027 Long-term capital lease obligations 3,420 Deferred tax liabilities 14,454 Other long-term liabilities 23,435 Total liabilities assumed 69,171 Total identifiable net assets 108,392 Fair value of noncontrolling interest (9,961 ) Goodwill 184,143 Net assets acquired $ 282,574
Schedule of pro forma financial information	Pro forma financial information is summarized as follows: Three Months Ended (pro forma, unaudited, in thousands, except per share amounts) March 31, Revenue $ 85,100 Net loss attributable to BioTelemetry, Inc. (6,100 ) Net loss per common share attributable to BioTelemetry, Inc.: Basic $ (0.19 ) Diluted $ (0.19 ) Weighted average number of common shares outstanding: Basic 32,123 Diluted 32,123

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Schedule of inventory	Inventory consists of the following: (in thousands) March 31, December 31, Raw materials and supplies $ 3,861 $ 3,128 Finished goods 2,492 2,204 Total inventory $ 6,353 $ 5,332

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of contingent payments associated with acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent payments associated with acquisitions that occurred during the year ended December 31, 2016: Three Months Ended (in thousands) March 31, March 31, Beginning balance $ 700 $ 3,305 Changes in fair value of contingent consideration (700 ) (605 ) Ending balance $ — $ 2,700

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amounts of goodwill by segment	The following table presents the carrying amount of goodwill allocated to our reportable segments, as well as the changes to goodwill during the three months ended March 31, 2018 : Reporting Segment (in thousands) Healthcare Research Corporate and Other Total Balance at December 31, 2017 $ 198,273 $ 16,293 $ 8,539 $ 223,105 Measurement period adjustment 594 — — 594 Balance at March 31, 2018 $ 198,867 $ 16,293 $ 8,539 $ 223,699
Schedule of finite-lived intangible assets	The gross carrying amounts and accumulated amortization of our intangible assets are as follows: Estimated Useful Life (Years) (in thousands, except years) March 31, December 31, Customer relationships 5 - 15 $ 143,174 $ 143,174 Technology including internally developed software 3 - 10 16,180 15,953 Backlog 1 - 4 6,860 6,860 Covenants not to compete 5 - 7 1,040 1,040 Total intangible assets, gross 167,254 167,027 Customer relationships (14,354 ) (10,868 ) Technology including internally developed software (9,184 ) (8,573 ) Backlog (5,245 ) (5,052 ) Covenants not to compete (857 ) (827 ) Total accumulated amortization (29,640 ) (25,320 ) Total intangible assets, net $ 137,614 $ 141,707

Equity Method Investment (Table

Equity Method Investment (Tables)	3 Months Ended
	Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Summary of investment	A summary of our investment in WellBridge is as follows: Three Months Ended (in thousands) March 31, March 31, Beginning balance $ 1,431 $ 1,125 Loss in equity method investment (139 ) (95 ) Ending balance $ 1,292 $ 1,030

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Schedule of accrued expenses	Accrued liabilities consists of the following: (in thousands) March 31, December 31, Compensation $ 10,783 $ 13,086 Professional fees 1,904 1,587 Squeeze-out — 2,885 Severance 758 1,605 Non-income taxes 1,345 588 Interest 341 306 Other 6,508 5,998 Total $ 21,639 $ 26,055

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock option activity	Stock option and PSO activity is summarized as follows: Stock Options Performance Stock Options Number of Shares Weighted Average Exercise Price Number of Shares Weighted Average Exercise Price Outstanding as of December 31, 2017 3,574,439 $ 10.78 150,000 $ 20.41 Granted 185,806 33.15 — — Forfeited (53,077 ) 28.37 — — Exercised (102,493 ) 12.94 — — Outstanding as of March 31, 2018 3,604,675 $ 11.61 150,000 $ 20.41
Summary of certain additional information with respect to options	The table below summarizes certain additional information with respect to our options: Three Months Ended (in thousands, except per option amounts) March 31, March 31, Aggregate intrinsic value of options outstanding at period end $ 73,400 $ 73,660 Aggregate intrinsic value of options exercisable at period end 65,819 59,376 Aggregate intrinsic value of options exercised during the period 2,164 3,752 Cash received from the exercise of stock options during the period 1,327 1,981 Weighted average grant date fair value per option during the period $ 19.61 $ 15.31
Summary of RSU activity	RSU and PSU activity is summarized as follows: Restricted Stock Units Performance Stock Units Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Units outstanding as of December 31, 2017 467,129 $ 13.76 — — Granted 79,474 32.99 63,345 $ 37.79 Forfeited (3,730 ) 17.84 — — Vested (186,650 ) 10.33 — — Units outstanding as of March 31, 2018 356,223 $ 19.81 63,345 $ 37.79
Schedule of aggregate market values	Additional information about our RSUs is summarized as follows: Three Months Ended (in thousands) March 31, March 31, Aggregate market value of RSUs vested during the period $ 6,395 $ 4,265
Schedule of aggregate stock-based compensation expense	Our aggregate stock-based compensation expense is summarized as follows: Three Months Ended (in thousands) March 31, March 31, Stock options $ 1,111 $ 596 Performance stock options — 1,534 Restricted stock units 720 813 Employee stock purchase plan 234 115 Total stock-based compensation expense $ 2,065 $ 3,058

Other Charges (Tables)

Other Charges (Tables)	3 Months Ended
	Mar. 31, 2018
Other Income and Expenses [Abstract]
Summary of expenses	A summary of these expenses is as follows: Three Months Ended (in thousands) March 31, March 31, Legal fees $ 1,536 $ 982 Professional fees 1,227 1,160 Severance and employee related costs 1,997 185 Change in fair value of contingent consideration (700 ) (605 ) Other costs 1,025 17 Total $ 5,085 $ 1,739

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Summary of financial information concerning the entity's reportable segments	During the year ended December 31, 2017 we reclassified research and development costs associated with cardiovascular devices utilized by our Research segment from the Corporate and Other category to the Healthcare segment to synchronize our external reporting with the way our chief operating decision maker reviews the segment performance and makes decisions about the reportable segments. (in thousands) Healthcare Research Corporate and Other Consolidated Three Months Ended March 31, 2018 Revenue $ 80,551 $ 11,244 $ 2,701 $ 94,496 Income/(loss) before income taxes 17,724 786 (13,616 ) 4,894 Depreciation and amortization 11,436 1,010 (2,618 ) 9,828 Capital expenditures 5,064 291 (1,417 ) 3,938 (reclassified, in thousands) Healthcare Research Corporate and Other Consolidated Three Months Ended March 31, 2017 Revenue $ 42,511 $ 9,324 $ 4,046 $ 55,881 Income/(loss) before income taxes 11,759 378 (12,807 ) (670 ) Depreciation and amortization 2,861 1,033 (179 ) 3,715 Capital expenditures 2,890 — 77 2,967

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Accounts Receivable and Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Bad debt expense	$ 4,879	$ 2,791

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - Credit Concentration Risk - Accounts Receivable - customer	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Concentration Risk
Number of major customers	1	1
Third Party Payor Medicare
Concentration Risk
Concentration risk, percentage	16.00%	21.00%

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Noncontrolling interests (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Jul. 12, 2017
Noncontrolling interests
Net income/(loss)	$ 5,036	$ 196
LifeWatch
Noncontrolling interests
Ownership interests acquired (as a percent)				97.00%
Ownership interest (as a percent)			100.00%
LifeWatch Turkey | LifeWatch Turkey
Noncontrolling interests
Ownership interest (as a percent)	55.00%
Net Assets	$ 100
Net income/(loss)	$ (2,100)

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Segment Information (Details)	3 Months Ended
	Mar. 31, 2018segment
Accounting Policies [Abstract]
Number of reportable segments	2

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Disaggregated revenue	$ 94,496
Deferred revenue	5,064	$ 4,298
Healthcare
Disaggregation of Revenue [Line Items]
Disaggregated revenue	80,551
Research
Disaggregation of Revenue [Line Items]
Disaggregated revenue	11,244
Deferred revenue	5,100
Recognition of deferred revenue	1,500
Other
Disaggregation of Revenue [Line Items]
Disaggregated revenue	2,701
Remote cardiac monitoring services - Medicare
Disaggregation of Revenue [Line Items]
Disaggregated revenue	30,215
Remote cardiac monitoring services - Medicare | Healthcare
Disaggregation of Revenue [Line Items]
Disaggregated revenue	30,215
Remote cardiac monitoring services - Medicare | Research
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Remote cardiac monitoring services - Medicare | Other
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Remote cardiac monitoring services - commercial payors
Disaggregation of Revenue [Line Items]
Disaggregated revenue	50,336
Remote cardiac monitoring services - commercial payors | Healthcare
Disaggregation of Revenue [Line Items]
Disaggregated revenue	50,336
Remote cardiac monitoring services - commercial payors | Research
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Remote cardiac monitoring services - commercial payors | Other
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Clinical trial support and related services
Disaggregation of Revenue [Line Items]
Disaggregated revenue	11,244
Clinical trial support and related services | Healthcare
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Clinical trial support and related services | Research
Disaggregation of Revenue [Line Items]
Disaggregated revenue	11,244
Clinical trial support and related services | Other
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Technology devices, consumable and related services
Disaggregation of Revenue [Line Items]
Disaggregated revenue	2,701
Technology devices, consumable and related services | Healthcare
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Technology devices, consumable and related services | Research
Disaggregation of Revenue [Line Items]
Disaggregated revenue	0
Technology devices, consumable and related services | Other
Disaggregation of Revenue [Line Items]
Disaggregated revenue	$ 2,701

Acquisitions - LifeWatch AG (De

Acquisitions - LifeWatch AG (Details) - USD ($)	Jul. 12, 2017	Jan. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Fair value of liabilities assumed:
Goodwill			$ 223,699,000	$ 223,105,000
LifeWatch
Acquisitions
Ownership interests acquired (as a percent)	97.00%
Consideration in common stock (in shares)	3,615,840	58,786
Fair value of BioTelemetry common stock issued	$ 116,800,000	$ 2,000,000
Cash consideration	165,800,000	$ 2,900,000
Ownership interest (as a percent)				100.00%
Goodwill, amount deductible	0
Measurement period adjustment, reducing non-income tax receivables			600,000
Fair value of assets acquired:
Cash and cash equivalents	4,303,000
Healthcare accounts receivable	9,467,000
Inventory	1,136,000
Prepaid expenses and other current assets	3,798,000
Property and equipment	28,241,000
Other assets	713,000
Identifiable intangible assets:
Total identifiable intangible assets	129,905,000
Total assets acquired	177,563,000
Fair value of liabilities assumed:
Accounts payable	10,424,000
Accrued liabilities	9,747,000
Current portion of capital lease obligations	4,664,000
Current portion of long-term debt	3,027,000
Long-term capital lease obligations	3,420,000
Deferred tax liabilities	14,454,000
Other long-term liabilities	23,435,000
Total liabilities assumed	69,171,000
Total identifiable net assets	108,392,000
Fair value of noncontrolling interest	(9,961,000)
Goodwill	184,143,000
Net assets acquired	282,574,000
Acquisition related costs			$ 0
LifeWatch | Customer relationships
Identifiable intangible assets:
Total identifiable intangible assets	$ 126,900,000
Weighted Average Life (Years)	10 years
LifeWatch | Technology
Identifiable intangible assets:
Total identifiable intangible assets	$ 3,005,000
Weighted Average Life (Years)	3 years

Acquisitions - Pro Forma Financ

Acquisitions - Pro Forma Financial Information LifeWatch AG (Details) - LifeWatch $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Unaudited pro forma information
Revenue | $	$ 85,100
Net loss attributable to BioTelemetry, Inc. | $	$ (6,100)
Net loss per common share attributable to BioTelemetry, Inc.:
Basic | $ / shares	$ (0.19)
Diluted | $ / shares	$ (0.19)
Weighted average number of common shares outstanding:
Basic | shares	32,123
Diluted | shares	32,123

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory
Raw materials and supplies	$ 3,861	$ 3,128
Finished goods	2,492	2,204
Total inventory	$ 6,353	$ 5,332

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration	$ (700)	$ (605)
Telcare
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration	(700)
ePatch Division
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of contingent consideration		$ (600)
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, fair value	$ 199,200		$ 199,400

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Contingent Payments (Details) - Contingent Consideration Liability - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 700	$ 3,305
Changes in fair value of contingent consideration	(700)	(605)
Ending balance	$ 0	$ 2,700

Goodwill - Changes In Carrying

Goodwill - Changes In Carrying Amounts (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Changes in the carrying amounts of goodwill by segment
December 31, 2017	$ 223,105
Measurement period adjustment	594
March 31, 2018	223,699
Healthcare
Changes in the carrying amounts of goodwill by segment
December 31, 2017	198,273
Measurement period adjustment	594
March 31, 2018	198,867
Research
Changes in the carrying amounts of goodwill by segment
December 31, 2017	16,293
Measurement period adjustment	0
March 31, 2018	16,293
Corporate and Other
Changes in the carrying amounts of goodwill by segment
December 31, 2017	8,539
Measurement period adjustment	0
March 31, 2018	$ 8,539

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Gross Carrying Amounts and Accumulated Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 167,254	$ 167,027
Total accumulated amortization	(29,640)	(25,320)
Total intangible assets, net	137,614	141,707
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross	143,174	143,174
Total accumulated amortization	$ (14,354)	(10,868)
Customer relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	5 years
Customer relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	15 years
Technology including internally developed software
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 16,180	15,953
Total accumulated amortization	$ (9,184)	(8,573)
Technology including internally developed software | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	3 years
Technology including internally developed software | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	10 years
Backlog
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 6,860	6,860
Total accumulated amortization	$ (5,245)	(5,052)
Backlog | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	1 year
Backlog | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	4 years
Covenants not to compete
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross	$ 1,040	1,040
Total accumulated amortization	$ (857)	$ (827)
Covenants not to compete | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	5 years
Covenants not to compete | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	7 years

Equity Method Investment (Detai

Equity Method Investment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Schedule of Equity Method Investments [Roll Forward]
Loss on equity method investment	$ (139)	$ (95)
Well Bridge Health Inc
Schedule of Equity Method Investments
Percentage of ownership interest in the voting stock	32.10%
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	$ 1,431	1,125
Loss on equity method investment	(139)	(95)
Ending balance	$ 1,292	$ 1,030

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Compensation	$ 10,783	$ 13,086
Professional fees	1,904	1,587
Squeeze-out	0	2,885
Severance	758	1,605
Non-income taxes	1,345	588
Interest	341	306
Other	6,508	5,998
Total	$ 21,639	$ 26,055

Credit Agreement (Details)

Credit Agreement (Details) - USD ($)	Jul. 12, 2017	Mar. 31, 2018	Mar. 31, 2017
Credit Agreement
Principal payments on long-term debt		$ 513,000	$ 312,000
LifeWatch
Credit Agreement
Principal payments on long-term debt	$ 3,000,000
HFS
Credit Agreement
Principal payments on long-term debt	24,900,000
Suntrust Bank
Credit Agreement
Percentage of capital stock of U.S. based subsidiaries		65.00%
Suntrust Bank | LifeWatch
Credit Agreement
Percentage of capital stock of U.S. based subsidiaries		65.00%
Suntrust Bank | LIBOR
Credit Agreement
Spread on variable interest rate (as a percent)		2.00%
Suntrust Bank | Base Rate
Credit Agreement
Spread on variable interest rate (as a percent)		1.00%
Suntrust Bank | Term Loan
Credit Agreement
Aggregate term loan principal at inception	205,000,000
Carrying amount of term loan		$ 199,200,000
Unamortized deferred financing cost		5,300,000
Suntrust Bank | Term Loan | January 2018 to December 2018
Credit Agreement
Principal amount of quarterly installment payments		500,000
Suntrust Bank | Term Loan | January 2019 to December 2019
Credit Agreement
Principal amount of quarterly installment payments		1,300,000
Suntrust Bank | Term Loan | January 2020 to December 2020
Credit Agreement
Principal amount of quarterly installment payments		3,800,000
Suntrust Bank | Term Loan | January 2021 to December 2021
Credit Agreement
Principal amount of quarterly installment payments		$ 5,100,000
Suntrust Bank | Revolving credit facility
Credit Agreement
Undrawn line of credit	$ 50,000,000
Unused commitment fee, percentage		0.30%

Equity (Details)

Equity (Details) - USD ($) $ in Thousands	Jul. 12, 2017	Jan. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Equity [Abstract]
Common stock, shares authorized			200,000,000	200,000,000
Common stock, shares issued			32,794,129	32,460,668
Common stock, shares outstanding			32,794,129	32,460,668
Preferred stock, shares authorized			10,000,000
Preferred stock, shares issued			0	0
Acquisitions
Noncontrolling interest			$ 2,000	$ 1,054
LifeWatch
Acquisitions
Number of shares issued in business acquisition	3,615,840	58,786
LifeWatch Turkey
Acquisitions
Noncontrolling interest			$ 2,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)planshares
Stock-based compensation
Number of stock plans | plan	3
2008 Plan
Stock-based compensation
Common stock available for grant (in shares)	0
2017 Omnibus Incentive Plan
Stock-based compensation
Common stock available for grant (in shares)	2,498,284
Stock Options
Stock-based compensation
Vesting period	4 years
Total compensation cost of options granted but not yet vested | $	$ 12.5
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	3 years
Stock Options | Maximum
Stock-based compensation
Expiration period	10 years
PSUs
Stock-based compensation
Granted (in shares)	63,345
Restricted stock units
Stock-based compensation
Granted (in shares)	79,474
Vesting period	3 years
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	2 years

Stock-Based Compensation - Outs

Stock-Based Compensation - Outstanding Stock Options (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Stock Options
Number of Shares
Outstanding as of December 31, 2017 (in shares) | shares	3,574,439
Granted (in shares) | shares	185,806
Forfeited (in shares) | shares	(53,077)
Exercised (in shares) | shares	(102,493)
Outstanding as of March 31, 2018 (in shares) | shares	3,604,675
Weighted Average Exercise Price
Outstanding as of December 31, 2017 (in dollars per share) | $ / shares	$ 10.78
Granted (in dollars per share) | $ / shares	33.15
Forfeited (in dollars per share) | $ / shares	28.37
Exercised (in dollars per share) | $ / shares	12.94
Outstanding as of March 31, 2018 (in dollars per share) | $ / shares	$ 11.61
Performance Stock Options
Number of Shares
Outstanding as of December 31, 2017 (in shares) | shares	150,000
Granted (in shares) | shares	0
Forfeited (in shares) | shares	0
Exercised (in shares) | shares	0
Outstanding as of March 31, 2018 (in shares) | shares	150,000
Weighted Average Exercise Price
Outstanding as of December 31, 2017 (in dollars per share) | $ / shares	$ 20.41
Granted (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	0
Exercised (in dollars per share) | $ / shares	0
Outstanding as of March 31, 2018 (in dollars per share) | $ / shares	$ 20.41

Stock-Based Compensation - Aggr

Stock-Based Compensation - Aggregate Intrinsic Value of Options (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock-based compensation
Aggregate intrinsic value of options outstanding at period end	$ 73,400	$ 73,660
Aggregate intrinsic value of options exercisable at period end	65,819	59,376
Aggregate intrinsic value of options exercised during the period	2,164	3,752
Cash received from the exercise of stock options during the period	$ 1,327	$ 1,981
Weighted average grant date fair value per option during the period (in usd per share)	$ 19.61	$ 15.31

Stock-Based Compensation - RSUs

Stock-Based Compensation - RSUs and PSUs (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Restricted stock units
Number of Shares
Units outstanding as of December 31, 2017 (in shares)	467,129
Granted (in shares)	79,474
Forfeited (in shares)	(3,730)
Vested (in shares)	(186,650)
Units outstanding as of March 31, 2018 (in shares)	356,223
Weighted Average Grant Date Fair Value
Units outstanding as of December 31, 2017 (in dollars per shares)	$ 13.76
Granted (in dollars per share)	32.99
Forfeited (in dollars per share)	17.84
Vested (in dollars per share)	10.33
Units outstanding as of March 31, 2018 (in dollars per shares)	$ 19.81
Aggregate market value of RSUs vested during the period	$ 6,395	$ 4,265
PSUs
Number of Shares
Units outstanding as of December 31, 2017 (in shares)	0
Granted (in shares)	63,345
Forfeited (in shares)	0
Vested (in shares)	0
Units outstanding as of March 31, 2018 (in shares)	63,345
Weighted Average Grant Date Fair Value
Units outstanding as of December 31, 2017 (in dollars per shares)	$ 0
Granted (in dollars per share)	37.79
Forfeited (in dollars per share)	0
Vested (in dollars per share)	0
Units outstanding as of March 31, 2018 (in dollars per shares)	$ 37.79

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option and RSU Narrative (Details)	3 Months Ended
	Mar. 31, 2018USD ($)shares
Stock-based compensation
PSU's reserved for issuance (in shares) | shares	63,345
Stock Options
Stock-based compensation
Total compensation cost of options granted but not yet vested	$ 12,500,000
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	3 years
PSUs
Stock-based compensation
Compensation expense related to PSUs	$ 0
Restricted stock units
Stock-based compensation
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	2 years
Stock-based compensation expense related to nonvested awards	$ 6,800,000

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - Employee stock purchase plan - USD ($)	1 Months Ended	3 Months Ended
	May 31, 2017	Mar. 31, 2018
Stock-based compensation
Remaining shares available under current Plan (in shares)	500,000	387,274
Maximum amount that employees may contribute through payroll deductions	$ 21,500
Percentage of the fair market price on the first day of the offering period or on the day of purchase (percent)	85.00%
Common stock purchased (in shares)		65,477
Proceeds from the issuance of shares of common stock		$ 1,200,000

Stock-Based Compensation - Ag56

Stock-Based Compensation - Aggregate Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock-based compensation
Total stock-based compensation expense	$ 2,065	$ 3,058
Stock Options
Stock-based compensation
Total stock-based compensation expense	1,111	596
Performance Stock Options
Stock-based compensation
Total stock-based compensation expense	0	1,534
Restricted stock units
Stock-based compensation
Total stock-based compensation expense	720	813
Employee stock purchase plan
Stock-based compensation
Total stock-based compensation expense	$ 234	$ 115

Other Charges (Details)

Other Charges (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Other Income and Expenses [Abstract]
Legal fees	$ 1,536	$ 982
Professional fees	1,227	1,160
Severance and employee related costs	1,997	185
Change in fair value of contingent consideration	(700)	(605)
Other costs	1,025	17
Total	$ 5,085	$ 1,739

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Benefit from income taxes	$ 142	$ 866
Deferred tax asset	$ 17,988		$ 17,681

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)segment	Mar. 31, 2017USD ($)
Segment information
Number of operating segments | segment	2
Revenue	$ 94,496	$ 55,881
Income/(loss) before income taxes	4,894	(670)
Depreciation and amortization	9,828	3,715
Capital expenditures	3,938	2,967
Operating segments | Healthcare
Segment information
Revenue	80,551	42,511
Income/(loss) before income taxes	17,724	11,759
Depreciation and amortization	11,436	2,861
Capital expenditures	5,064	2,890
Operating segments | Research
Segment information
Revenue	11,244	9,324
Income/(loss) before income taxes	786	378
Depreciation and amortization	1,010	1,033
Capital expenditures	291	0
Other
Segment information
Revenue	2,701	4,046
Income/(loss) before income taxes	(13,616)	(12,807)
Depreciation and amortization	(2,618)	(179)
Capital expenditures	$ (1,417)	$ 77